Ensar Halilovic

发表

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Therapeutic strategies for inhibiting oncogenic BRAF signaling.

David B Solit, D. Solit, Ensar Halilovic, 2008, Current opinion in pharmacology.

BRAF mutation predicts MEK-dependence in non-small cell lung cancer (NSCLC).

C. Pratilas, N. Rosen, M. Janakiraman, 2007 .

Centrosomal Anchoring of Protein Kinase C βII by Pericentrin Controls Microtubule Organization, Spindle Function, and Cytokinesis*

A. Newton, Ensar Halilovic, S. Doxsey, 2004, Journal of Biological Chemistry.

The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1

Ensar Halilovic, S. Jeay, J. Wuerthner, 2016, Neuroendocrinology.

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Matthew D. Shirley, Hao Wang, P. Hammerman, 2021, Cancer Research.

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

C. Emery, S. Roman-Roman, Ensar Halilovic, 2016, Oncotarget.

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

J. Esteve, Bernard Pereira, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract #1417: Identification and biological characterization of exon 4 KRAS mutations by MALDI-TOF Mass Spectrometry based genotyping

M. Ladanyi, S. Jhanwar, N. Rosen, 2009 .

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

Ensar Halilovic, T. Paíno, L. San-Segundo, 2020, Haematologica.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

G. Ayers, Douglas B. Johnson, Ensar Halilovic, 2019, Science Translational Medicine.

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Ensar Halilovic, A. Wei, K. Porkka, 2021, Blood.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Barry S Taylor, Marc Ladanyi, Alex Lash, 2010, Cancer research.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

G. Demetri, R. Dummer, S. Ferretti, 2021, British Journal of Cancer.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

B. Taylor, A. Viale, Weiqing Wang, 2010, Proceedings of the National Academy of Sciences.

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

W. Sellers, Nanxin Li, D. Ruddy, 2017, eLife.

A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase

Ensar Halilovic, S. Doxsey, Agata Jurczyk, 2003, The Journal of cell biology.

Genetic predictors of MEK dependence in non-small cell lung cancer.

William Pao, Barry S Taylor, Neal Rosen, 2008, Cancer research.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

S. Chandarlapaty, J. Wolchok, C. Pratilas, 2012, Cancer cell.

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

Q. She, N. Rosen, D. Solit, 2010, Cancer cell.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Annette S. Kim, A. Letai, C. Paweletz, 2020, Cancer cell.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Joel Greshock, Levi A Garraway, Fred Harbinski, 2016, Cancer research.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

F. Colland, Youzhen Wang, A. Roberts, 2018, Leukemia.

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advancedTP53wt acute leukemias

D. DeAngelo, Ensar Halilovic, S. Jeay, 2017 .

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

W. Sellers, Q. She, N. Rosen, 2010, Cancer research.

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.

S. Roman-Roman, Ensar Halilovic, S. Alsafadi, 2020, European journal of cancer.

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

F. Colland, Youzhen Wang, Ensar Halilovic, 2019, Experimental and Molecular Therapeutics.

Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies

F. Colland, Youzhen Wang, Ensar Halilovic, 2019, Experimental and Molecular Therapeutics.

Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma

J. Blay, A. Italiano, S. Ferretti, 2018, Clinical Trials.

Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma

G. Caponigro, R. Schlegel, M. Wiesmann, 2014 .

A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase

Ensar Halilovic, S. Doxsey, Agata Jurczyk, 2003, The Journal of cell biology.

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

E. Thompson, A. Roberts, Ensar Halilovic, 2022, Blood.

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

W. Tilley, Y. Haupt, Ensar Halilovic, 2020, bioRxiv.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

P. Hammerman, G. Dranoff, J. Engelman, 2018, Clinical research.

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study.

J. Blay, A. Italiano, S. Ferretti, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.